1. Janssen Biotech, Inc. Highlights of prescribing information. Zytiga® (abiraterone acetate) tablets. U.S. FDA revised 02/2018.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202379s024lbl.pdf
. Accessed 1 Mar 2018.
2. Janssen-Cilag International NV. Summary of product characteristics Zytiga 250 mg tablets. EMA updated: 11/2017.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002321/WC500112858.pdf
. Accessed 30 Mar 2018. Accessed 01 Mar 2018.
3. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small E. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010.
https://doi.org/10.1200/JCO.2009.24.1281
.
4. National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management, clinical guideline. 2014.
https://www.nice.org.uk/guidance/CG175?UNLID=
. Accessed 1 Mar 2018.
5. National Institute for Health and Care Excellence. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. 2016.
https://www.nice.org.uk/guidance/ta259
. Accessed 1 Mar 2018.